Table 1

Profile of HAM/TSP patients enrolled and improvement of motor function in the lower extremities 12 weeks after treatment
Age (years) Sex Duration of illuness (years) Concomitant therapy Intermittent self-catheterization OMDSa Spasticity of the lower extremities
Case no. Immunomodulator Drug for neurogenic bladder
Anticholinergic α1 blocker Before treatment After treatment Before treatment Improvementb
1 80 Female 23 No Yes Yes 6 6 Yes Yes
2 64 Female 16 No Yes Yes 6 6 Yes Yes
3 57 Male 51 PSL/ IFN-α Yes Yes 6 6 Yes Yes
4 51 Female 36 No Yes Yes 9 9 Yes Yes
5 67 Female 3 No Yes 3 3 No
6 61 Female 30 No Yes 5 5 Yes Yes
7 68 Female 12 No Yes No 4 4 Yes Yes
8 64 Male 11 PSL Yes No 5 5 Yes No
9 66 Male 23 PSL Yes Yes 9 9 Yes Yes
10 76 Male 23 No No 6 6 Yes Yes
11 53 Female 7 No Yes 6 6 Yes No
12 62 Female 12 PSL Yes Yes 4 4 No
13 44 Female 22 No Yes 6 6 Yes No
14 56 Male 10 No Yes Yes 5 5 Yes Yes
15 71 Female 45 No Yes Yes 9 9 No
16 78 Female 18 No Yes Yes 5 5 Yes Yes
17 50 Female 19 No No 5 5 Yes Yes
18 63 Female 29 No Yes Yes 8 8 Yes Yes
19 62 Female 9 PSL Yes Yes 8 8 Yes No
20 60 Female 34 No Yes Yes 2 1 No
21 46 Female 26 PSL Yes No 2 1 Yes Yes
22 31 Female 7 No Yes No 4 3 Yes Yes
23 56 Male 18 No Yes 10 10 No
24 56 Male 16 IFN-α No 2 2 Yes Yes
Remarks mean ± SD; mean ± SD; % improvement:
60.1 ± 11.2 20.9 ± 12.1 78.9 (P = 0.0003)c

aOsame’s motor function score (OMDS) was rated from 0 to 13 according to the disability grade [13].

bImprovement in spasticity of more than 1 grade according to the modifiedAshworth scale [14].

cStatistical significance was determined by the McNemar test.

IFNα interferon α, PSL prednisolone.

Nakamura et al.

Nakamura et al. BMC Medicine 2013 11:182   doi:10.1186/1741-7015-11-182

Open Data